DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Chlorthalidone Compared to Hydrochlorothiazide on Endothelial Function

Information source: Creighton University
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Chlorthalidone 12.5 mg (Drug); Hydrochlorothiazide 25 mg (Drug); Placebo (Drug)

Phase: Phase 4

Status: Withdrawn

Sponsored by: Creighton University

Official(s) and/or principal investigator(s):
Ahmed Aboeata, MBBCh, Principal Investigator, Affiliation: Creighton University

Summary

Chlorthalidone will result in improved endothelial function compared to hydrochlorothiazide as measured by flow mediated vasodilatation.

Clinical Details

Official title: The Effect of Chlorthalidone Compared to Hydrochlorothiazide on Endothelial Function in Hypertensive Patients: A Pilot Study

Study design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome: Flow mediated vasodilatation

Detailed description: This is a randomized, double-blind, crossover study to evaluate chlorthalidone and hydrochlorothiazide and their effects on endothelial function in hypertensive patients. Subjects will receive chlorthalidone 12. 5 mg, hydrochlorothiazide 25 mg, and placebo each for 4 weeks with a 1 week washout between study periods. Sequence of study drugs will be randomized. Flow mediated vasodilatation will be measured at baseline and after each treatment period.

Eligibility

Minimum age: 19 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Age 19 or older

- Diagnosis of hypertension

- Current blood pressure > 120/80 mm Hg

Exclusion Criteria:

- Use of a thiazide-type diuretic within the last 1 month

- Known allergy to any study medications

- History of gout or hyperuricemia

- SCr >/= 1. 8 mg/dl or CrCl < 25 ml/min

- Pregnancy or breastfeeding or planning to become pregnant during study period

- Dementia or cognitive impairment

- Hypokalemia

- Acute coronary syndrome or stroke within 6 months

- Current use of sildenafil, tadalafil, or vardenafil

Locations and Contacts

Creighton University, Omaha, Nebraska 68131, United States
Additional Information

Starting date: March 2013
Last updated: March 24, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017